The DayOne Accelerator Program, a three-month, equity-free initiative based in Basel, Switzerland, is now accepting applications from early-stage global healthtech and techbio startups. It specifically targets ventures focused on pharmaceutical research and development, offering a structured pathway for innovation within a major European life sciences hub.
The DayOne program is equity-free and fee-free, a non-dilutive growth opportunity crucial for pre-seed to Series A companies managing cash flow and valuation. According to fundsforNGOs, it supports ventures that have raised less than USD 10 million in dilutive funding, clearly defining its target cohort.
What We Know So Far
- The DayOne Accelerator is a three-month hybrid program located in Basel, Switzerland, according to fundsforNGOs.
- It specifically invites applications from healthtech and techbio startups working on pharmaceutical R&D, as reported by the same source.
- The program is structured to be both equity-free and fee-free for all participating startups, the program details state.
- Applicants must have raised less than USD 10 million in dilutive funding to be considered for a spot in the cohort.
- Selected high-performing ventures may become eligible for up to CHF 50,000 in non-dilutive funding after the program concludes, fundsforNGOs reports.
- Initial support includes potential travel assistance of up to CHF 1,000 for an in-person bootcamp in Basel.
DayOne Accelerator Program structure and curriculum
The DayOne Accelerator Program for healthtech startups operates on a three-month hybrid model, integrating remote activities with on-site components in Basel, Switzerland. This structure enables global participation while offering direct access to the local innovation ecosystem. The curriculum specifically targets healthtech and techbio companies, with an emphasis on enhancing pharmaceutical R&D processes.
Eligibility is open to international startups from pre-seed through Series A, specifically those having secured less than USD 10 million in total dilutive funding. This financial gate ensures the program serves early-stage companies in a critical growth and fundraising phase, where non-dilutive support is particularly impactful. The global call for applications aims to attract a diverse pool of innovators to the Basel region.
Key benefits for startups in DayOne Program
The DayOne program offers a non-dilutive framework, allowing startups to participate without surrendering equity or paying fees, thus preserving their ownership and capital. This is complemented by direct financial support: selected ventures may receive up to CHF 1,000 in travel support to attend the initial bootcamp, as reported by fundsforNGOs, which lowers the barrier to entry for international teams.
Beyond the initial phase, the program offers further non-dilutive opportunities based on performance. High-performing or specifically selected startups may gain access to as much as CHF 50,000 in non-dilutive funding. This capital can be used to advance research, product development, or market entry without affecting the company's cap table. This performance-based incentive provides a clear goal for participants throughout the accelerator's duration.
In addition to financial incentives, the program provides tangible infrastructure support. The source material indicates that certain startups may be offered up to 12 months of office space in Basel following the conclusion of the accelerator. This provides a physical foothold in a key European life sciences cluster, facilitating networking, partnership development, and talent acquisition for ventures looking to establish or expand their presence in the region. As applications for the DayOne Accelerator Program for Healthtech Startups are now open, ventures can assess these benefits against their strategic goals.
